• SKIP TO CONTENT
  • SKIP NAVIGATION
  • Patient Resources
    • COVID-19 Patient Resource Center
    • Clinical Trials
    • Search Clinical Trials
    • Patient Notification System
    • What is Clinical Research?
    • Volunteering for a Clinical Trial
    • Understanding Informed Consent
    • Useful Resources
    • FDA Approved Drugs
  • Professional Resources
    • Research Center Profiles
    • Clinical Trial Listings
    • Market Research
    • FDA Approved Drugs
    • Training Guides
    • Books
    • eLearning
    • Events
    • Newsletters
    • JobWatch
    • White Papers
    • Patient Education
    • SOPs
    • eCFR and Guidances
  • White Papers
  • Trial Listings
  • Advertise
  • COVID-19
  • iConnect
  • Sign In
  • Create Account
  • Sign Out
  • My Account
Home » Lambda acquires Biovail’s early phase unit

Lambda acquires Biovail’s early phase unit

August 10, 2010
CenterWatch Staff

As part of transforming from a maker of primarily generic drugs to a maker of innovator products, and also as part of its impending merger with Aliso Viejo, Calif.-based Valeant, Toronto-based Biovail has sold its 194-bed, phase I/bioanalystics lab to Indian CRO Lambda Therapeutic Research for $6 million.

The purchase gives 11-year-old Lambda, headquartered in Ahmedabad, more than 600 beds, placing the company among the five largest phase I groups in the world, according to Neal McCarthy, managing director of the CRO-focused investment banking firm Fairmount Partners, which worked on the deal.

The sale makes sense for Biovail. “Bovail intended to change their focus and this is a logical next step for them,” said McCarthy.

Christopher Ore, formerly general manager of Biovail’s contract research division and now Lambda’s chief operating officer, said Lambda was already a dominant independent phase I player in India and the acquisition is part of its recent strategy to offer phase I in other parts of the world. In 2007, the company acquired the Polish phase I company CBK-MPR Pharma. The following year, it picked up another European holding: Pharm V Solutions in London.

“This acquisition gives us the opportunity to mirror the direction our clients have been going in over the last two or three years,” said Ore. “I have seen lots of outsourcing to India and Europe.”

He added that Canada has recently become an important part of that mix as phase I units can get studies up and running in about 10 days, due to changes in regulatory requirements. Previously, it took about 60 days. “The regulatory filing period for an early phase trial is the most advantageous in the world,” Ore said.

Biovail Contract Research is comprised of two Toronto locations totaling about 46,000 square feet housing six study clinics, almost 200 beds, as well as a bioanalytical laboratory and clinical data management department.

The units, located about a mile apart, have done approximately 3,500 phase I, bioavailability/bioequivalence and/or drug-interaction studies on 400 different chemical entities. Combined, they have 100 employees and a database with more than 100,000 potential volunteers.

On June 21, Biovail announced in June that it would buy Valeant for $3.3 billion. As part of the merger, Biovail will become Valeant Pharmaceuticals International. The new firm will specialize in central nervous system therapies and dermatology treatments, with a focus on Canada and emerging markets. The company plans to cut its newly combined workforce by 15% to 20%, or 4,400 people.

Biovail has experienced accounting scandals in recent years, including allegations that it manipulated financial results. The firm is also alleged to have paid doctors to prescribe its blood pressure drug Cardizem LA.

Upcoming Events

  • 15Apr

    Five Telltale Signs You’re Ready for an Electronic TMF System

  • 26Apr

    MAGI's Clinical Research vConference — Spring 2021

  • 06May

    The World of Post-COVID-19 Clinical Trials: How to Prepare for What’s Coming Next

Featured Products

  • Regenerative Medicine – Steps to Accelerate Development : PDF

    Regenerative Medicine: Steps to Accelerate Development

  • Clinical Trial Agreements — A Guide to Key Words and Phrases : PDF

    Clinical Trial Agreements: A Guide to Key Words and Phrases

Featured Stories

  • Clinical-Trial-Brainstorming

    FDA, Industry Tackle Problem of Including Older Adults in Trials

  • ClinicalTrialNetwork-360x240.png

    National Community-Based Research Network Would Improve Reach of Trials

  • Bottleneck-360x240.png

    Sites Face Trials Bottleneck After Pandemic, But Also Opportunities

  • AsktheExpertsBadge-360x240.png

    Ask the Experts: Genetic Research and IBC Oversight Requirements

Standard Operating Procedures for Risk-Based Monitoring of Clinical Trials

The information you need to adapt your monitoring plan to changing times.

Learn More Here
  • About Us
  • Contact Us
  • Privacy Policy
  • Do Not Sell My Personal Information

Footer Logo

300 N. Washington St., Suite 200, Falls Church, VA 22046, USA

Phone 617.948.5100 – Toll free 866.219.3440

Copyright © 2021. All Rights Reserved. Design, CMS, Hosting & Web Development :: ePublishing